HomeBUSINESS
BUSINESS

Opdivo/Yervoy Combo Gets 1st Line RCC Nod in South Korea
(Oct.10.2018)

Ono Pharmaceutical said on October 9 it has received approval in South Korea for a combination therapy of its PD-1 inhibitor Opdivo (nivolumab) and Bristol-Myers Squibb’s CTLA-4 inhibitor Yervoy (ipilimumab) for the frontline treatment of renal cell carcinoma (RCC) ...
(LOG IN FOR FULL STORY)